Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy

Jiang,Haijiao; Wang,He; Wang,Shiyu; Pei,Zhengtong; Fu,Zhimin; Fang,Changqing; Wang,Jian; Lu,Qingjie; Wang,Enhua; Li,Jianhua

doi:10.3892/mmr.2014.3141

Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy

Authors:
- Haijiao Jiang
- He Wang
- Shiyu Wang
- Zhengtong Pei
- Zhimin Fu
- Changqing Fang
- Jian Wang
- Qingjie Lu
- Enhua Wang
- Jianhua Li
View Affiliations

Affiliations: Department of Pathology, College of Basic Medical Sciences and First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110013, P.R. China, Department of Pathology and Lab Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA, Department of Medicine, The Commonwealth Medical College, Scranton, PA 18905, USA, Department of Pathology, Second Affiliated Hospital of China Medical University, Shenyang, Liaoning 110011, P.R. China
Published online on: December 30, 2014 https://doi.org/10.3892/mmr.2014.3141
Pages: 3523-3532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between the expression of excision repair cross‑complementing gene 1 (ERCC1), thymidylate synthase (TYMS), ribonuleotide reductase M1 (RRM1), βIII‑tubulin (TUBB3), non‑muscle myosin II, myoglobin and MyoD1 in metastatic lung adenocarcinoma, and clinical outcomes with platinum‑based chemotherapy treatment is not well‑established. Recently, increasing attention has been focused on the involvement of ERCC1, TYMS, RRM1 and TUBB3 in the development of drug resistance. There has been less research into the role of muscle myosin II, myoglobin and MyoD1 in the pathogenesis of lung cancer, although these genes are known to have important functions within tumor cells. In the current study, malignant pleural effusion from 116 patients with untreated lung adenocarcinoma diagnosed between 2011 and 2012, were collected. The protein expression levels of ERCC1, TYMS, RRM1 and TUBB3 were evaluated with immunocytochemistry and western blot analysis. The expression levels of non‑muscle myosin II, myoglobin and MyoD1 were measured in a subset of 50 patients, treated with platinum‑based chemotherapy. The association of each of these seven factors with one another, as well as with patient survival were analyzed. Immunohistochemistry demonstrated that the percentage of pleural fluid samples from patients with lung adenocarcinoma expressing ERCC1, TYMS, RRM1 and TUBB3 was 37, 36.2, 82.7 and 69.8%, respectively. In the subset of 50 patients in whom the remaining factors were analyzed, the percentage expressing non‑muscle myosin II was 48%, for myoglobin the figure was 40% and for MyoD1 it was 38%. There was a positive correlation between each pair of the above seven molecules with the exception of TYMS and RRM1. Expression of ERCC1, TYMS, TUBB3, non‑muscle myosin II, myoglobin and MyoD1 genes was associated with decreased survival in patients with metastatic lung adenocarcinoma. Expression of ERCC1, TYMS, TUBB3, non‑muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum‑based chemotherapy. These factors may be used as clinical biomarkers to predict the biological behavior and chemoresistance of tumor cells, and the survival of patients with lung carcinoma.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Marshall HM, Leong SC, Bowman RV, et al: The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. Respirology. 17:247–260. 2012. View Article : Google Scholar
3	Morgensztern D, Waqar S, Subramanian J, et al: Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 7:1485–1489. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zahreddine H and Borden LB: Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 4:282013. View Article : Google Scholar : PubMed/NCBI
5	Suh DH, Kim MK, Kim HS, Chung HH and Song YS: Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. J Cancer Prev. 18:227–234. 2013. View Article : Google Scholar
6	Zhang L, Yang H and Xu J: Gene expression significance in personalized medicine of non-small-cell lung cancer and gene expression analyzing platforms. Curr Drug Metab. 12:455–459. 2011. View Article : Google Scholar : PubMed/NCBI
7	Sancar A and Reardon JT: Nucleotide excision repair in E. coli and man. Adv Protein Chem. 69:43–71. 2004. View Article : Google Scholar : PubMed/NCBI
8	Van Den Broeck A, Nissou D, Brambilla E, et al: Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis. 33:320–325. 2012. View Article : Google Scholar
9	Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
10	Xianjun F, Xiu-guang Q, Li Z, et al: ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pak J Med Sci. 30:488–492. 2014.
11	Gangjee A, Yu J, McGuire JJ, et al: Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J Med Chem. 43:3837–3851. 2000. View Article : Google Scholar : PubMed/NCBI
12	Sigmond J, Backus HH, Wouters D, et al: Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol. 66:431–438. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wang T, Chuan Pan C, Rui Yu J, et al: Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. PLoS one. 8:e742842013. View Article : Google Scholar : PubMed/NCBI
14	Rosell R, Cobo M, Isla D, et al: Pharmacogenomics and gemcitabine. Ann Oncol. 17(Suppl 5): 13–16. 2006. View Article : Google Scholar
15	Vilmar AC, Santoni-Rugiu E and Sorensen JB: Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol. 24:309–314. 2013. View Article : Google Scholar
16	Katsetos CD, Herman MM and Mörk SJ: Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton. 55:77–96. 2003. View Article : Google Scholar : PubMed/NCBI
17	McCarroll JA, Gan PP, Liu M and Kavallaris M: betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 70:4995–5003. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kim JH and Adelstein RS: LPA(1)-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol. 226:2881–2893. 2011. View Article : Google Scholar : PubMed/NCBI
19	Merx MW, Flögel U, Stumpe T, et al: Myoglobin facilitates oxygen diffusion. FASEB J. 15:1077–1079. 2001.PubMed/NCBI
20	Flonta SM, Arena S, Pisacane A, et al: Expression and functional regulation of myoglobin in epithelial cancers. Am J Pathol. 175:201–206. 2009. View Article : Google Scholar : PubMed/NCBI
21	Jin W, Liu Y, Chen L, et al: Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. Breast Cancer Res Treat. 125:699–713. 2011. View Article : Google Scholar
22	Soleimani VD, Yin H, Jahani-Asl A, et al: Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. Mol Cell. 47:457–468. 2012. View Article : Google Scholar : PubMed/NCBI
23	Polo V and Besse B: Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol. 25:1283–1293. 2014. View Article : Google Scholar
24	Hildebrandt MA, Gu J and Wu X: Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 5:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ota S, Ishii G, Goto K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009. View Article : Google Scholar
26	Das M, Riess JW, Frankel P, et al: ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer. 77:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
27	Gao Z, Han B, Shen J, et al: ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer. Exp Ther Med. 2:811–815. 2011.
28	Shimizu T, Nakanishi Y, Nakagawa Y, et al: Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res. 32:4589–4596. 2012.PubMed/NCBI
29	Dong X, Hao Y, Wei Y, et al: Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS One. 9:e923202014. View Article : Google Scholar : PubMed/NCBI
30	Gong W, Zhang X, Wu J, et al: RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer. 75:374–380. 2012. View Article : Google Scholar
31	Dumontet C, Isaac S, Souquet PJ, et al: Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 92:E25–E30. 2005.PubMed/NCBI
32	Sève P, Isaac S, Trédan O, et al: Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486. 2005. View Article : Google Scholar
33	Ferrandina G, Zannoni GF, Martinelli E, et al: Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res. 12:2774–2779. 2006. View Article : Google Scholar : PubMed/NCBI
34	Tommasi S, Mangia A, Lacalamita R, et al: Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer. 120:2078–2085. 2007. View Article : Google Scholar : PubMed/NCBI
35	Portyanko A, Kovalev P, Gorgun J and Cherstvoy E: beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch. 454:541–548. 2009. View Article : Google Scholar : PubMed/NCBI
36	Katsetos CD and Dráber P: Tubulins as therapeutic targets in cancer: from bench to bedside. Curr Pharm Des. 18:2778–2792. 2012. View Article : Google Scholar : PubMed/NCBI
37	Maus MK, Mack PC, Astrow SH, et al: Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non small-cell lung cancer: implications for therapy. J Thoracic Oncol. 8:582–586. 2013.
38	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
39	Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
40	Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
41	Kajiyama H, Shibata K, Terauchi M, et al: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 31:277–283. 2007.PubMed/NCBI
42	Hsu DS, Lan HY, Huang CH, et al: Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
43	Kocaefe C, Balci D, Hayta BB and Can A: Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. Stem Cell Rev. 6:512–522. 2010. View Article : Google Scholar : PubMed/NCBI
44	Giarnieri E, De Vitis C, Noto A, et al: EMT markers in lung adenocarcinoma pleural effusion spheroid cells. J Cell Physiol. 228:1720–1726. 2013. View Article : Google Scholar
45	Oleksiewicz U, Daskoulidou N, Liloglou T, et al: Neuroglobin and myoglobin in non-small cell lung cancer: expression, regulation and prognosis. Lung Cancer. 74:411–418. 2011. View Article : Google Scholar : PubMed/NCBI
46	Xiong D, Ye YL, Chen MK, et al: Non-muscle myosin II is an independent predictor of overall survival for cystectomy candidates with early-stage bladder cancer. Oncol Rep. 28:1625–1632. 2012.PubMed/NCBI